-
Pfizer/BioNTech mRNA vaccine to prevent influenza enters the clinic
Time of Update: 2021-11-05
The flexibility of mRNA technology and its rapid production may allow better virus strain matching, stronger supply reliability, and improved influenza vaccine effectiveness .
In addition, in the case of pandemic influenza, mRNA technology can allow rapid and large-scale production of effective vaccines .
-
Deqi Pharmaceutical Celiniso Phase II clinical trial application approved in China for the treatment of myelofibrosis
Time of Update: 2021-11-05
According to the National Comprehensive Cancer Network (NCCN) guidelines, intermediate-risk-2 and high-risk patients who are not suitable for allogeneic hematopoietic stem cell transplantation can receive JAK inhibitor ruxolitinib or if the platelet count is ≥50×109/L fedratinib treatment (NCCN, 2020) .
-
Ou Tangjing(R) (Engligliflozin Tablets) new indication for adult patients with heart failure with preserved ejection fraction has submitted an application for registration in China
Time of Update: 2021-11-05
Shanghai, October 11, 2021/PRNewswire/ - On September 30, 2021, Boehringer Ingelheim-Eli Lilly jointly announced that it has formally submitted its Diabetes Alliance's SGLT2 to the China National Medical Products Administration Center for Drug Evaluation Inhibitor Otangjing® (generic name: Enpagliflozin tablets) is used for the registration application of new indications for adult patients with heart failure with preserved ejection fraction .
-
Borui Biologics ``Infliximab'' biosimilar drug approved for marketing
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsOn September 28, the National Food and Drug Administration (NMPA) announced that the infliximab for injection declared by Hisun Biologics, a wholly-owned subsidiary of Zhejiang Borui Biopharmaceutical Co.
Retrieved Sep 28, 2021, from https:// Hisun Biologics Infliximab for injection (proposed trade name: Ambaite®) was declared and listed.
-
Nuocheng Jianhua released the 2021 semi-annual report with these latest developments and milestones
Time of Update: 2021-11-05
Obutinib for the treatment of multiple sclerosis phase 2 clinical global study completed the first subject administration in the United States, and is currently actively starting to enroll patients in China and Europe .
-
Voriconazole tablets, a subsidiary of Jingfeng Pharmaceuticals, obtained the drug registration certificate
Time of Update: 2021-11-05
In addition, voriconazole also has a bactericidal effect against other pathogenic fungi in vitro, including bacteria that are less sensitive to current antifungal drugs, such as Actinomyces and Fusarium .
-
Will there be a "cut-off" incident in the centralized procurement of Chinese patent medicines?
Time of Update: 2021-11-05
So, as a manufacturing company, if the centralized procurement wins the bid, in order to prevent the price of raw materials from rising, can it choose to reserve a large amount of medicinal materials for emergency needs?Of course this is fine!However, the current initial goal of the relevant government departments to prepare for centralized procurement is to work on the "large quantities and high prices" of proprietary Chinese medicine products .
-
China's first new crown "special effect medicine" screen?
Time of Update: 2021-11-05
The health and hygiene zone established for the first time by the China International Trade in Services, where intravenous injection of COVID-19 human immunoglobulin (pH4), referred to as "new crown special immunity" and recombinant fully human anti-new crown virus monoclonal antibody injection-two This special medicine and the second-generation vaccine against mutant strains such as Delta are the world's first releases .
-
Pantoprazole Sodium for Injection, a wholly-owned subsidiary of Sialon Pharmaceuticals, passed the consistency evaluation of generic drugs
Time of Update: 2021-11-05
On September 8, Sialon Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Hunan Sialon Pharmaceutical, had recently obtained the "Approval Notice for Supplementary Drug Ap
-
New formulation of Pfizer JAK inhibitor approved in China to treat rheumatoid arthritis
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsOn September 13, Pfizer announced that the National Medical Products Administration (NMPA) of China has officially approved the marketing application of its oral JAK inhibitor tofacitib citrate sustained-release tablets for insufficient efficacy against methotrexate Or adult patients with moderate to severe active rheumatoid arthritis (RA) who cannot tolerate it can be used in combination with methotrexate or other non-biological disease-improving anti-rheumatic drugs (DMARD) .
-
Takeda China supports the 4th National Gastroesophageal Reflux Disease Awareness Week
Time of Update: 2021-11-05
Lu Zhaofeng, Executive Vice President of the China Association for the Promotion of International Health Care, said: "Since the launch of the National Gastroesophageal Reflux Disease Awareness Week in 2018, we have carried out various forms of disease science education, and we have been working hard to improve disease awareness and attention.
-
Fu'an Pharmaceutical obtained drug registration certificate for Esomeprazole Sodium for Injection
Time of Update: 2021-11-05
On September 16, Fu'an Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Chu Pharmaceutical, had recently received a drug registration certificate for Esomeprazole Sodium for Injection approved and issued by the National Medical Products Administration .
-
Amlodipine benzoate dry suspension, a wholly-owned subsidiary of Poinsettia, obtained the notification of drug clinical trial
Time of Update: 2021-11-05
On September 14, Poinsettia issued an announcement stating that its wholly-owned subsidiary, Poinsettia Pharmaceuticals, declared that the dry suspension of amlodipine benzoate (acceptance number: CXH
-
Glipizide tablets, a wholly-owned subsidiary of Zhongsheng Pharmaceutical, passed the consistency evaluation of generic drugs
Time of Update: 2021-11-05
There are three main types of oral hypoglycemic drugs in clinical use.
According to the chemical drug terminal competition pattern database of Chinese city public hospitals on Mynet, the sales of glipizide tablets from 2018 to 2020 are RMB 222.
-
Bristol-Myers Squibb’s PD-1 Inhibitor’s New Indication Application for Listing Enters "Under Approval"
Time of Update: 2021-11-05
According to the announcement of the National Food and Drug Administration (NMPA) of China, Bristol-Myers Squibb Company (BMS) Nivolumab Injection (Odivo)’s new indication listing application status has been updated to “under review”, which means The drug is expected to usher in new indications in China in the near future .
-
Lose again!
Time of Update: 2021-11-05
This study aims to evaluate the efficacy and safety of Merck's TGF-β/PD-L1 bifunctional fusion protein bintrafusp alfa combined with gemcitabine and cisplatin in the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) .
-
TOP14 R&D efficiency PK of pharmaceutical companies: Who is more efficient in independent R&D vs. external innovation?
Time of Update: 2021-11-05
However, the difference is that most of the R&D output of Novartis and GlaxoSmithKline comes from patent research projects, while the R&D output of Pfizer, Merck and Gilead is more derived from mergers and acquisitions and licensing .
-
Merck’s “New Crown Medicine” submitted its listing application for the third climax in the anti-infective field?
Time of Update: 2021-11-05
S. Food and Drug Administration (FDA) for an emergency use authorization (EUA) of Molnupiravir for the treatment of mild to moderate COVID-19 that has developed a severe risk and/or hospitalization risk Adult patients with pneumonia .
-
CureVac abandons the development of the first-generation COVID-19 vaccine
Time of Update: 2021-11-05
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn October 12, the German company CureVac announced that the development of the COVID-19 vaccine will focus on the development of the second-generation mRNA candidate vaccine in cooperation with GSK, and its first-generation COVID-19 candidate vaccine CVnCoV will be obtained from the European Medicines Agency ( EMA) withdrawn in the current approval process .
-
A large number of pharmacies apply for the "Internet Drug Information Service Qualification Certificate" to prepare for online drug sales
Time of Update: 2021-11-05
Proof of providing Internet drug servicesProof of providing Internet drug servicesRecently, the Hebei Provincial Food and Drug Administration issued an announcement that according to the relevant provisions of the "Internet Drug Information Service Management Measures", after review, Hebei Haishengtang Pharmacy Chain Co.
